External Source

Are There Significant Differences Among The 1st And 2nd Generation Egfr Tkis?

2015 3:25
Synopsis
Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant ...

You Might Also Like

Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors? 3:28
Are There Clinically Significant Differences Among The Third...
2015
Are There Distinctions Among Currently Available Oral EGFR Inhibitors? 2:22
Are There Distinctions Among Currently Available Oral Egfr I...
2015
Differences Among Specific EGFR Mutations 2:19
Differences Among Specific Egfr Mutations
2015
Second- and Third-Generation TKIs in EGFR-Mutated NSCLC 2:36
Second- And Third-generation Tkis In Egfr-mutated Nsclc
2019
Two mechanisms of acquired resistance to EGFR TKIs 1:05
Two Mechanisms Of Acquired Resistance To Egfr Tkis
2013
Third Generation EGFR TKIs for Acquired Resistance 3:07
Third Generation Egfr Tkis For Acquired Resistance
2017
Should Third Generation EGFR Inhibitors Be Used Before or After Progression? 3:28
Should Third Generation Egfr Inhibitors Be Used Before Or Af...
2015
Dr. Philip Bonomi: Gefitinib and Later Generations of EGFR Inhibitors 1:01
Dr. Philip Bonomi: Gefitinib And Later Generations Of Egfr I...
2013
Examining the Combination of EGFR Inhibition Plus Chemotherapy in Lung Cancer 1:18
Examining The Combination Of Egfr Inhibition Plus Chemothera...
2020
Does the Specific EGFR Mutation Matter When Choosing an Oral EGFR Inhibitor? 3:15
Does The Specific Egfr Mutation Matter When Choosing An Oral...
2015
Activity of EGFR TKIs in patients with NSCLC with uncommon EGFR mutations 2:45
Activity Of Egfr Tkis In Patients With Nsclc With Uncommon E...
2021
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.